SCHEDULE: Soleus Capital Discloses Vericel Stake

Soleus Capital Master Fund, L.P. and associated entities have reported beneficial ownership of 2.8% of Vericel Corp. common stock as of June 30, 2026.

Summary

• Soleus Capital Master Fund, L.P., along with related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, have filed a Schedule 13G.
• This filing indicates that these entities collectively beneficially own 1,458,882 shares of Vericel Corp. common stock.
• This ownership represents 2.8% of the total outstanding shares of Vericel Corp. common stock as of July 24, 2026.
• The filing is an amendment (Amendment No. 1) and the event date requiring the filing is June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• Each of SCG, Soleus Capital, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds that acquire a significant stake in a public company. This filing indicates Soleus Capital's investment activity in Vericel Corp.

Stakeholder Impact

• Shareholders may note the increased stake by Soleus Capital, which could signal investor confidence or potential future activism.

Key Dates

Keywords

Vericel Corp, Schedule 13G, Beneficial Ownership, Soleus Capital, Common Stock, Investment Management